600079 人福医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)6.4227.67113.30717.75311.168
总资产报酬率 ROA (%)3.1183.6585.9106.9553.884
投入资产回报率 ROIC (%)4.0554.7757.8039.1795.009

边际利润分析
销售毛利率 (%)48.18344.55345.80643.52542.747
营业利润率 (%)15.2079.91514.05615.74010.945
息税前利润/营业总收入 (%)15.83310.90415.03916.39813.608
净利润/营业总收入 (%)12.4106.99211.47913.7498.848

收益指标分析
经营活动净收益/利润总额(%)98.750114.31391.83972.56082.758
价值变动净收益/利润总额(%)2.55710.14510.15525.65614.445
营业外收支净额/利润总额(%)-2.531-4.094-1.872-2.626-3.501

偿债能力分析
流动比率 (X)1.5411.4891.4851.2831.167
速动比率 (X)1.2851.2211.2111.0570.966
资产负债率 (%)43.00043.32044.48650.19255.793
带息债务/全部投入资本 (%)32.42432.33534.21940.18848.946
股东权益/带息债务 (%)194.978195.060179.446138.82197.364
股东权益/负债合计 (%)113.540111.435105.82383.16665.548
利息保障倍数 (X)15.8067.90812.11215.4594.486

营运能力分析
应收账款周转天数 (天)140.463122.512114.800115.106110.763
存货周转天数 (天)100.89091.70795.33893.42188.484